ReviewHematology/oncology clinics of North America2010
Epigenetic changes in the myelodysplastic syndrome.
Review in Hematology/oncology clinics of North America, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed.
- Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial.The Lancet. Haematology · 2019Trial
- Peripheral blood mononuclear cell proteome changes in patients with myelodysplastic syndrome.BioMed research international · 2015Trial
- Real-world study of use patterns and clinical outcomes for patients with myelodysplastic syndrome initiating oral decitabine and cedazuridine or intravenous/subcutaneous hypomethylating agents.Therapeutic advances in hematology · 2026Article
- Epigenetic alterations in Myeloid Malignancies.Advances in experimental medicine and biology · 2026Review
- Azanucleoside treatment leads to B-cell precursor acute lymphoblastic leukemia.Blood neoplasia · 2025Article
- Potential Diagnostic Value of Abnormal Pyroptosis Genes Expression in Myelodysplastic Syndromes (MDS): A Primary Observational Cohort Study.International journal of hematology-oncology and stem cell research · 2024Article
- Epigenetic Profiling ofCancers · 2023Article
- Antisenescence effect of REAC biomodulation to counteract the evolution of myelodysplastic syndrome.Physiological research · 2022Article
- The genetics of myelodysplastic syndromes and the opportunities for tailored treatments.Frontiers in oncology · 2022Review
- Review
- Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome.International journal of molecular sciences · 2021Review
- EnvIRONmental Aspects in Myelodysplastic Syndrome.International journal of molecular sciences · 2021Review
- Immune Dysregulation and Recurring Mutations in Myelodysplastic Syndromes Pathogenesis.Advances in experimental medicine and biology · 2021Review
- A novel treatment regimen of granulocyte colony-stimulating factor combined with ultra-low-dose decitabine and low-dose cytarabine in older patients with acute myeloid leukemia and myelodysplastic syndromes.Therapeutic advances in hematology · 2021Article
- Epigenetic modifiers in normal and aberrent erythropoeisis.Seminars in hematology · 2021Review
- Intracellular Pharmacokinetics of Pyrimidine Analogues used in Oncology and the Correlation with Drug Action.Clinical pharmacokinetics · 2020Review
- Cancer Epigenomics and Beyond: Advancing the Precision Oncology Paradigm.Journal of immunotherapy and precision oncology · 2020Review
- IGF‑IR promotes clonal cell proliferation in myelodysplastic syndromes via inhibition of the MAPK pathway.Oncology reports · 2020Article
- Changes of signal transductivity and robustness of gene regulatory network in the carcinogenesis of leukemic subtypes via microarray sample data.Oncotarget · 2018Article
- Targeting the Immune Microenvironment in Acute Myeloid Leukemia: A Focus on T Cell Immunity.Frontiers in oncology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Epigenetic mechanisms, such as DNA methylation and histone modifications, drive stable, clonally propagated changes in gene expression and can therefore serve as molecular mediators of pathway dysfunction in neoplasia. Myelodysplastic syndrome (MDS) is characterized by frequent epigenetic abnormalities, including the hypermethylation of genes that control proliferation, adhesion, and other characteristic features of this leukemia. Aberrant DNA hypermethylation is associated with a poor prognosis in MDS that can be accounted for by more rapid progression to acute myeloid leukemia. In turn, treatment with drugs that modify epigenetic pathways (DNA methylation and histone deacetylation inhibitors) induces durable remissions and prolongs life in MDS, offering some hope and direction in the future management of this deadly disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.